ClinicalTrials.gg
RecruitingNCT06843447Updated Nov 13, 2026

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

A Phase 1/2 interventional study of Raludotatug Deruxtecan and Carboplatin in Ovarian Cancer Recurrent, sponsored by Merck Sharp & Dohme LLC. Recruiting at 42 sites in 9 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 13, 2026First sites in South Korea, Taiwan and AustraliaTitle changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
605
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 166 studies testing carboplatin in Ovarian Neoplasms — 14 open to participants now, 21 under way, 6 of them phase 3. Carboplatin · Ovarian Neoplasms.

Planned enrollment
11th of 150
605 · median 48
Started
2025
with 2 others
Phase 1/2
19 of 166
1 open now
Primary completion
2029-03
later than 20 of 20 live
Registered
160th of 166
by date

Among the 166 studies testing carboplatin in Ovarian Neoplasms, this one is the 11th largest by planned enrollment of the 150 interventional ones that give a count, is one of 3 that started in 2025, is one of 19 in phase 1/2, reaches primary completion later than 20 of the 20 other live ones, and was the 160th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

14 of the 166 studies testing carboplatin in Ovarian Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies testing carboplatin in Ovarian Neoplasms, or all of them as a file.
02

Study summary

Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes.

Standard treatment (usual treatment) for people with high-grade serous ovarian cancer may include:

  • Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing
  • Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread

Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.

Read the detailed description

This study has 2 parts: Part 1 is a dose escalation phase of R-DXd. Part 2 is the expansion phase and will use the Recommended Phase 2 Dose (RP2D) of R-DXd determined in Part 1.

03

Conditions studied

  • Ovarian Cancer Recurrent

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has documented diagnosis of high-grade serous or high-grade endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
  • Participants in Part 1 cohorts and Part 2 Cohort A-2 Arms 1, 2, and 3, Cohort B-2, and Cohort C-2 Arm 3: Has per 1.1
  • Participants in Cohort A-1 Arms 2 and 3: Has disease after 1 to 3 and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
  • Participants in Cohort B-1 and Cohort B-2: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression \<6 months (\<180 days) after the last dose of platinum-based therapy (ie, platinum-resistant disease). Participants must have received no more than 1 prior bevacizumab-containing systemic treatment regimen
  • Participants in Cohort B-1, Cohort B-2, Cohort C-2 Arm 3, Cohort E-1 and if administering bevacizumab is planned in Cohort D or Cohort A-2 Arms 1, 2, or 3: Is a candidate for bevacizumab treatment
  • Has provided tumor tissue for biomarker research (all cohorts)
  • Has an performance status of 0 to 1
  • Participants in Cohort C-1, Cohort C-2 Arm 3, Cohort D, and Cohort E-1: Has relapsed disease after 1 prior line of therapy, radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease) and progressed during prior treatment with poly-ADP ribose polymerase inhibitor (PARPi) in the first-line setting
  • Participants in Cohort A-2 Arms 1, 2, and 3: Has relapsed disease after 1 prior line of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
  • Participants in Cohort C-2 Arms 1 and 2: Has a new, histologically confirmed diagnosis of International Federation of Gynecology and Obstetrics Stage III or Stage IV epithelial ovarian cancer (high-grade serous or high-grade endometrioid), fallopian tube cancer, or primary peritoneal cancer that is non-homologous recombination deficiency-positive
  • Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, PARPi first-line maintenance treatment for non- homologous recombination deficiency (HRD)-positive disease is not the preferred option for the participant
  • Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, bevacizumab treatment for non-HRD-positive disease is not the preferred option for the participant

Exclusion criteria

Exclusion Criteria:

  • Has any of the following within 6 months before allocation/randomization: cerebrovascular accident, , or other arterial thromboembolic event
  • Has uncontrolled or significant cardiovascular disease
  • Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, and any , connective tissue, or inflammatory disorders with potential pulmonary involvement, or prior pneumonectomy
  • Has ≥Grade 2 peripheral neuropathy
  • Has received prior treatment with cadherin-6-targeted agents
  • Has received prior systemic anticancer therapy including agents within 4 weeks or 5 half-lives (whichever is shorter) before allocation
  • Has received prior radiotherapy within 2 weeks of the start of study intervention, or has radiation-related toxicities, requiring
  • Receives chronic steroid treatment
  • Has known additional that is progressing or has required active treatment within the past 3 years
  • Has known active and/or carcinomatous meningitis
  • Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of prior steroid use, current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening
  • Has active infection requiring systemic therapy
  • -infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
605 participants (estimated)

Study arms

  • Experimental
    Cohort A-1 Arm 1 (R-DXd + Carboplatin Dose 1)

    Participants receive escalating doses of intravenous (IV) raludotatug deruxtecan (R-DXd) in combination with carboplatin at Dose 1. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive raludotatug deruxtecan until disease progression or discontinuation.

    Biological: Raludotatug Deruxtecan · Drug: Carboplatin · Drug: Rescue Medication

  • Experimental
    Cohort A-1 Arm 2 (R-DXd + Paclitaxel)

    Participants receive escalating doses of IV R-DXd in combination with paclitaxel. Participants can receive up to a maximum of six 3-week cycles of paclitaxel (approximately 4 months) and will receive R-DXd until disease progression or discontinuation.

    Biological: Raludotatug Deruxtecan · Drug: Paclitaxel · Drug: Rescue Medication

  • Experimental
    Cohort A-1 Arm 3 (R-DXd + Carboplatin Dose 2)

    Participants receive escalating doses of intravenous (IV) R-DXd in combination with carboplatin at Dose 2. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive R-DXd until disease progression or discontinuation.

    Biological: Raludotatug Deruxtecan · Drug: Carboplatin · Drug: Rescue Medication

  • Experimental
    Cohort B-1 (R-DXd + Bevacizumab)

    Participants receive escalating doses of IV R-DXd in combination with bevacizumab until disease progression or discontinuation.

    Biological: Raludotatug Deruxtecan · Biological: Bevacizumab · Drug: Rescue Medication

  • Experimental
    Cohort B-2 (R-DXd RP2D + Bevacizumab)

    Participants with platinum-resistant recurrent ovarian cancer (PRROC) receive recommended Phase 2 dose (RP2D) of IV R-DXd in combination with bevacizumab until disease progression or discontinuation.

    Biological: Raludotatug Deruxtecan · Biological: Bevacizumab · Drug: Rescue Medication

  • Experimental
    Cohort C-1 (R-DXd + Pembrolizumab)

    Participants receive escalating doses of IV R-DXd in combination with pembrolizumab. Participants can receive up to a maximum of thirty-five 3-week cycles of pembrolizumab (approximately 2 years) and will receive R-DXd until disease progression or discontinuation.

    Biological: Raludotatug Deruxtecan · Drug: Rescue Medication · Biological: Pembrolizumab

  • Experimental
    Cohort D (R-DXd +/- Bevacizumab)

    Participants with platinum-sensitive recurrent ovarian cancer (PSROC) receive IV R-DXd in combination with or without bevacizumab until disease progression or discontinuation.

    Biological: Raludotatug Deruxtecan · Biological: Bevacizumab · Drug: Rescue Medication

  • Experimental
    Cohort A-2 Arm 1 (R-DXd RP2D + Carboplatin +/- Bevacizumab)

    Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of carboplatin with or without bevacizumab, until disease progression or discontinuation.

    Biological: Raludotatug Deruxtecan · Drug: Carboplatin · Biological: Bevacizumab · Drug: Rescue Medication

  • Experimental
    Cohort A-2 Arm 2 (R-DXd RP2D + Paclitaxel +/- Bevacizumab)

    Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of paclitaxel with or without bevacizumab, until disease progression or discontinuation.

    Biological: Raludotatug Deruxtecan · Drug: Paclitaxel · Biological: Bevacizumab · Drug: Rescue Medication

  • Active comparator
    Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +/- Bevacizumab)

    Participants with PSROC will receive one of 3 regimens of investigator's choice of platinum-based doublet chemotherapy with or without bevacizumab. Platinum-based doublet chemotherapy will be administered for maximum of 8 cycles. Bevacizumab can be administered until disease progression or discontinuation.

    Drug: Carboplatin · Drug: Paclitaxel · Biological: Bevacizumab · Drug: Gemcitabine · Drug: Pegylated liposomal doxorubicin

  • Experimental
    Cohort E-1 (R-DXd + MK-2010)

    Participants receive escalating doses of IV R-DXd in combination with MK-2010. Participants can receive up to a maximum of thirty-five 3-week cycles of MK-2010 (approximately 2 years) and will receive R-DXd until disease progression or discontinuation.

    Biological: Raludotatug Deruxtecan · Drug: Rescue Medication · Drug: MK-2010

  • Experimental
    Cohort C-2 Arm 1 (Carboplatin + Paclitaxel + Pembrolizumab → R-DXd + Pembrolizumab)

    Participants will receive carboplatin (Dose 1 or Dose 2), paclitaxel (five 3-week cycles), and pembrolizumab during the induction phase. During the maintenance phase, participants will receive RP2D of IV R-DXd (up to 2 years; participants with PR or SD at 2 years may continue until disease progression) in combination with pembrolizumab (up to thirty-five 3-week cycles).

    Biological: Raludotatug Deruxtecan · Drug: Carboplatin · Drug: Paclitaxel · Biological: Pembrolizumab

  • Experimental
    Cohort C-2 Arm 2 (Carboplatin + Paclitaxel)

    Participants will receive carboplatin (Dose 1 or Dose 2) and paclitaxel (seven 3-week cycles), followed by standard of care observation.

    Drug: Carboplatin · Drug: Paclitaxel

  • Experimental
    Cohort C-2 Arm 3 (R-DXd + Pembrolizumab + Bevacizumab)

    Participants with PSROC will receive RP2D of R-DXd in combination with pembrolizumab (up to thirty-five 3-week cycles) and bevacizumab until progressive disease.

    Biological: Raludotatug Deruxtecan · Biological: Bevacizumab · Biological: Pembrolizumab

Interventions

  • IV infusion on Day 1 of every 3-week cycle.

    Also known as: MK-5909, R-DXd

  • IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

  • IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

  • BiologicalBevacizumab

    IV infusion on Day 1 of every 3-week cycle.

    Also known as: Includes, based on sourcing:, - Avastin®, - Alymsys®, - MVASI®, - Oyavas®, - Zirabev®, - Vegzelma®, - Aybintio®, - Breztri®

  • DrugRescue Medication

    Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

  • BiologicalPembrolizumab

    IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.

  • IV injection on days 1 and 8 of each 3-week Cycle

  • IV injection administered on Day 1 of each 4-week cycle

    Also known as: PLD

  • IV infusion on Day 1 of every 3-week cycle

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0)

    DLTs are defined as toxicities during the DLT evaluation period that are assessed by the investigator to be possibly, probably, or definitely related to study treatment and include: Grade 4 thrombocytopenia of any duration or Grade 3 thrombocytopenia lasting ≥7 days; Grade 3 or higher thrombocytopenia associated with clinically significant bleeding; Grade 4 lymphocytopenia lasting ≥14 days; Grade 4 anemia of any duration; any other Grade 4 hematologic toxicity lasting ≥7 days; febrile neutropenia Grade 3 or Grade 4 meeting pre-specifications; pre-specified hepatic organ toxicities; all Grade 3 or higher other nonhematologic toxicities except those pre-specified; other pre-specified nonhematologic toxicities; any delay in treatment with the planned dose of ≥21 days or discontinuation of treatment due to a toxicity during the DLT evaluation period, or Grade 5 toxicity. The number of participants with DLTs will be reported.

    Time frame: Up to 21 days

  2. Part 1: Number of Participants with One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more AEs will be reported.

    Time frame: Up to approximately 3 years

  3. Part 1: Number of Participants who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 3 years

  4. Part 2: Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

    Time frame: Up to approximately 3 years

  5. Part 2: Progression Free Survival (PFS) - Cohort C-2 Arm 1 and Arm 2

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Part 1: Objective Response Rate (ORR)

    ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumours version 1.1 (RECIST 1.1). ORR will be assessed by blinded independent central review (BICR).

    Time frame: Up to approximately 3 years

  2. Part 2: Duration of Response (DOR)

    For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by Blinded Independent Central Review (BICR) will be presented.

    Time frame: Up to approximately 3 years

  3. Part 2: PFS - Cohort A-2 Arm 2 and Arm 3

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.

    Time frame: Up to approximately 3 years

  4. Part 2: Overall Survival (OS)

    OS is defined as the time from the first dose of study treatment to death due to any cause.

    Time frame: Up to approximately 5 years

  5. Part 2: Number of Participants with One or More AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 3 years

  6. Part 2: Number of Participants who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 3 years

07

Study locations

41 of 42 sites recruiting
  • Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)
    New Haven, Connecticut 06510, United States
    Recruiting
    • Study Coordinator · Contact203-785-2404
  • The University of Louisville, James Graham Brown Cancer Center ( Site 0009)
    Louisville, Kentucky 40202, United States
    Recruiting
    • Study Coordinator · Contact502-562-3429
  • TRIALS 365 ( Site 0020)
    Shreveport, Louisiana 71103, United States
    Recruiting
    • Study Coordinator · Contact318-408-1198
  • Dana-Farber Cancer Institute ( Site 0015)
    Boston, Massachusetts 02215, United States
    Recruiting
    • Study Coordinator · Contact877-338-7425
  • Memorial Sloan Kettering Cancer Center ( Site 0003)
    New York, New York 10065, United States
    Recruiting
    • Study Coordinator · Contact212-639-2000
  • OU Health University of Oklahoma Medical Center ( Site 7000)
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
    • Study Coordinator · Contact405-271-1112
  • Texas Oncology - DFW ( Site 8000)
    Fort Worth, Texas 76104, United States
    Recruiting
    • Study Coordinator · Contact615-329-7430
  • Houston Methodist Hospital ( Site 0010)
    Houston, Texas 77030, United States
    Completed

    Not enrolling at this site — choose another above.

  • START Mountain Region ( Site 0008)
    West Valley City, Utah 84119, United States
    Recruiting
    • Study Coordinator · Contact801-907-4750
  • University of Virginia Health System ( Site 0011)
    Charlottesville, Virginia 22908, United States
    Recruiting
    • Study Coordinator · Contact434-924-9333
  • Western Health-Sunshine & Footscray Hospitals ( Site 1002)
    St Albans, Victoria 3021, Australia
    Recruiting
    • Study Coordinator · Contact+61402775432
  • Princess Margaret Cancer Centre ( Site 0101)
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Study Coordinator · Contact416-946-2818
  • Centre Hospitalier de l'Université de Montréal ( Site 0102)
    Montreal, Quebec H2X 0A9, Canada
    Recruiting
    • Study Coordinator · Contact514-890-8000
  • McGill University Health Centre ( Site 0100)
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
    • Study Coordinator · Contact514-934-1934x31975
  • Rambam Health Care Campus ( Site 0202)
    Haifa, 3109601, Israel
    Recruiting
    • Study Coordinator · Contact972-4-7776234
  • Shaare Zedek Medical Center ( Site 0201)
    Jerusalem, 9103102, Israel
    Recruiting
    • Study Coordinator · Contact+972-(0)2-6555424
  • Rabin Medical Center ( Site 0203)
    Petah Tikva, 4941492, Israel
    Recruiting
    • Study Coordinator · Contact+97239378076
  • Sheba Medical Center ( Site 0200)
    Ramat Gan, 5265601, Israel
    Recruiting
    • Study Coordinator · Contact972-3-5304498
  • National Cancer Center ( Site 2004)
    Goyang-si, Kyonggi-do 10408, South Korea
    Recruiting
    • Study Coordinator · Contact82319201760
  • Seoul National University Hospital ( Site 2000)
    Seoul, 03080, South Korea
    Recruiting
    • Study Coordinator · Contact+82220723511
  • Severance Hospital, Yonsei University Health System ( Site 2002)
    Seoul, 03722, South Korea
    Recruiting
    • Study Coordinator · Contact+82222282230
  • Asan Medical Center ( Site 2003)
    Seoul, 05505, South Korea
    Recruiting
    • Study Coordinator · Contact+82230103646
  • Samsung Medical Center ( Site 2001)
    Seoul, 06351, South Korea
    Recruiting
    • Study Coordinator · Contact82234101382
  • Institut Català d'Oncologia - L'Hospitalet ( Site 0302)
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
    Recruiting
    • Study Coordinator · Contact+34932607744
  • HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307)
    Majadhonda, Madrid 28222, Spain
    Recruiting
    • Study Coordinator · Contact+34 911917358
  • Clinica Universidad de Navarra ( Site 0301)
    Madrid, Madrid, Comunidad de 28027, Spain
    Recruiting
    • Study Coordinator · Contact+349135319207513
  • Hospital General Universitario de Valencia ( Site 0305)
    Valencia, Valenciana, Comunitat 46014, Spain
    Recruiting
    • Study Coordinator · Contact+34 963187527
  • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)
    Barcelona, 08035, Spain
    Recruiting
    • Study Coordinator · Contact+349325434528607
  • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)
    Madrid, 28040, Spain
    Recruiting
    • Study Coordinator · Contact34915504800 x2805
  • Hospital Universitario 12 de Octubre ( Site 0304)
    Madrid, 28041, Spain
    Recruiting
    • Study Coordinator · Contact+34913908626
  • Hospital Universitario Virgen de la Victoria ( Site 0306)
    Málaga, 29010, Spain
    Recruiting
    • Study Coordinator · Contact+34951032508
  • University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 0802)
    Basel, Canton of Basel-City 4031, Switzerland
    Recruiting
    • Study Coordinator · Contact+41613284214
  • CHUV (centre hospitalier universitaire vaudois) ( Site 0800)
    Lausanne, Canton of Vaud 1011, Switzerland
    Recruiting
    • Study Coordinator · Contact+41795567362
  • HOCH Health Ostschweiz ( Site 0801)
    Sankt Gallen, 9000, Switzerland
    Recruiting
    • Study Coordinator · Contact+41714941111
  • National Taiwan University Hospital ( Site 3001)
    Taipei, 100225, Taiwan
    Recruiting
    • Study Coordinator · Contact+886223123456
  • Chang Gung Medical Foundation-Linkou Branch ( Site 3002)
    Taoyuan, 33305, Taiwan
    Recruiting
    • Study Coordinator · Contact+88633281200
  • University Hospitals Sussex NHS Foundation Trust ( Site 0404)
    Brighton, East Sussex BN2 1ES, United Kingdom
    Recruiting
    • Study Coordinator · Contact+44 01273 696 955
  • Royal Marsden Hospital ( Site 0402)
    Fulham, England SW3 6JJ, United Kingdom
    Recruiting
    • Study Coordinator · Contact+442078118084
  • The Royal Marsden NHS Foundation Trust. ( Site 0403)
    Sutton, England SM2 5PT, United Kingdom
    Recruiting
    • Study Coordinator · Contact+442078118084
  • Barts Health NHS Trust ( Site 0401)
    London, London, City of E1 1RD, United Kingdom
    Recruiting
    • Study Coordinator · Contact020 7377 7000
  • Guy s & St Thomas NHS Foundation Trust ( Site 0400)
    London, London, City of SE1 3SS, United Kingdom
    Recruiting
    • Study Coordinator · Contact+44 020 7188 7188
  • The Christie NHS Foundation Trust ( Site 0405)
    Manchester, M20 4BX, United Kingdom
    Recruiting
    • Study Coordinator · Contact+441619187689
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

7 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Mar 2029, 47 months after the start.

Of 116 industry-sponsored phase 1/2 interventional studies under Ovarian Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 88. This study's planned 47 months is below that.

Counting every sponsor, half of 173 studies reached it within 65 months; a quarter within 44 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2025
First posted
Feb 25, 2025
StartActual
Apr 15, 2025
Primary completionEst.
Mar 27, 2029
CompletionEst.
Feb 7, 2031
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added — first sites in South Korea, Taiwan and Australia
Show 9 added (5 South Korea, 2 Taiwan, 1 Canada, 1 Australia)
  • Asan Medical Center ( Site 2003) · Seoul, South Korea
  • National Cancer Center ( Site 2004) · Goyang-si, South Korea
  • Princess Margaret Cancer Centre ( Site 0101) · Toronto, Canada
  • Seoul National University Hospital ( Site 2000) · Seoul, South Korea
  • Severance Hospital, Yonsei University Health System ( Site 2002) · Seoul, South Korea
  • National Taiwan University Hospital ( Site 3001) · Taipei, Taiwan
  • Western Health-Sunshine & Footscray Hospitals ( Site 1002) · St Albans, Australia
  • Chang Gung Medical Foundation-Linkou Branch ( Site 3002) · Taoyuan, Taiwan
  • Samsung Medical Center ( Site 2001) · Seoul, South Korea
across 6 updates, Oct 15, 2026 – Nov 13, 2026
Title
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Oct 15, 2026
Show all 7 updates
  1. Nov 13, 2026
    1 site added
    Show site
    • Samsung Medical Center ( Site 2001) · Seoul, South Korea
  2. Nov 10, 2026
    1 site added
    Show site
    • Chang Gung Medical Foundation-Linkou Branch ( Site 3002) · Taoyuan, Taiwan
    + 1 other change: verification date
  3. Oct 30, 2026
    1 site added — first site in Australia
    Show site
    • Western Health-Sunshine & Footscray Hospitals ( Site 1002) · St Albans, Australia
    + 1 other change: references
  4. Oct 21, 2026
    4 sites added — first site in Taiwan
    Show 4 added (2 South Korea, 1 Canada, 1 Taiwan)
    • Princess Margaret Cancer Centre ( Site 0101) · Toronto, Canada
    • Seoul National University Hospital ( Site 2000) · Seoul, South Korea
    • Severance Hospital, Yonsei University Health System ( Site 2002) · Seoul, South Korea
    • National Taiwan University Hospital ( Site 3001) · Taipei, Taiwan
  5. Oct 19, 2026
    1 site added
    Show site
    • National Cancer Center ( Site 2004) · Goyang-si, South Korea
  6. Oct 15, 2026
    1 site added — first site in South Korea
    Show site
    • Asan Medical Center ( Site 2003) · Seoul, South Korea
    Title A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
  7. Oct 6, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06843447
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Feb 25, 2025
Start date
Apr 15, 2025
Primary completion
Mar 27, 2029 (estimated)
Completion
Feb 7, 2031 (estimated)
Last update
Nov 13, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Raludotatug deruxtecan · Carboplatin · Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010

Start the discussion